ABSTRACT

This chapter presents a framework for guiding policy-making with respect to constructing an innovative medical and pharmaceutical industry in China. The concept of pharmaceutical innovation presupposes that some unmet health need exists in a given population, for which a new product would provide benefit for societal and individual well-being. In order to improve systems/infrastructure aspects of clinical trial processes, it is vital to understand the reasons for complications and failures in current studies. The International Conference on Harmonization was founded in 1990 as a partnership of the industry and regulator sections from three geographies – the US, the EU and Japan. The UK Ministry announced a new 2013 initiative to change their Patents Act in order to cut red tape and improve the environment for the development of new drugs. Several recent publications regarding changing disease patterns, globally and in specific countries many nations have experienced remarkable changes in prevalent health challenges of their citizens.